文献速递前列腺癌

FUTURE试验中MRI阴性且系统活检阴性后显著性前列腺癌的发生率

Incidence of significant prostate cancer after negative MRI and systematic biopsy in the FUTURE trial.
PubMed 文献 · BJU Int · 2022-09-11

FUTURE试验子研究纳入665例既往系统活检阴性但临床怀疑前列腺癌的男性,其中431例mpMRI阴性(PI-RADS≤2)进入生化随访。中位随访41个月后13例(3.0%)诊断为显著性前列腺癌,标准化发病比为4.3(95%CI 2.3-7.4)。作者认为风险虽低但高于一般人群,需进一步研究风险适应监测策略。

要点

  • 既往活检阴性且mpMRI阴性者中位随访41个月后显著性前列腺癌发生率为3.0%。
  • 显著性前列腺癌标准化发病比为4.3(95%CI 2.3-7.4),高于一般人群。
  • 欧洲前列腺癌筛查随机研究风险计算器预测活检阳性风险较高和复查MRI可疑(PI-RADS≥3)是显著性前列腺癌的显著预测因素。

核心结论

  • 既往活检阴性且mpMRI阴性后显著性前列腺癌风险低,但尽管mpMRI阴性预测值高,显著性前列腺癌风险仍高于一般人群。
  • 作者认为需要更多研究关注生化和影像引导的风险适应诊断监测策略。

研究设计与样本

  • 前瞻性研究,纳入多中心随机对照试验中2014年至2017年间的665例既往系统活检阴性且前列腺特异性抗原持续升高和/或直肠指检可疑的男性,均接受mpMRI。
  • 所有系统活检阴性且mpMRI PI-RADS≤2的患者进入生化随访,随访数据截至2021年12月,通过回顾机构医院记录和荷兰病理登记库(PALGA)收集。

主要发现

  • 共431例患者mpMRI阴性并进入生化随访,中位随访41(23-57)个月后38例诊断为前列腺癌,其中13例(3.0%)为显著性前列腺癌。
  • 显著性前列腺癌的标准化发病比为4.3(95%CI 2.3-7.4),总超额8例。
  • 基于欧洲前列腺癌筛查随机研究风险计算器的活检阳性风险较高和复查MRI可疑(PI-RADS≥3)是显著性前列腺癌的显著预测因素。

关键数值与推荐

  • 显著性前列腺癌定义为Gleason≥3+4/国际泌尿病理学会分级分组≥2。
  • mpMRI阴性定义为PI-RADS≤2。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To assess the proportion of clinically significant (cs) prostate cancer (PCa) found during follow-up in patients with negative systematic biopsy (SB) followed by non-suspicious multiparametric magnetic resonance imaging (mpMRI) and persistent clinical suspicion of PCa compared to the general population. PATIENTS AND METHODS: A prospective study in a subgroup of patients from a multicentre randomized controlled trial was conducted between 2014 and 2017, including 665 men with prior negative SB with a persistent elevated prostate-specific antigen and/or suspicious digital rectal examination undergoing mpMRI. All patients with negative SB and Prostate Imaging-Reporting and Data System (PI-RADS) ≤2 on mpMRI entered biochemical follow-up. Follow-up data until December 2021 were collected by reviewing institutional hospital records and the Dutch Pathology Registry (PALGA). The primary outcome was the observed number of csPCa (Gleason ≥3 + 4/International Society of Urological Pathology grade group ≥2) cases during follow-up compared to the expected number in the general population (standardized incidence ratio [SIR]). RESULTS: In total, 431 patients had non-suspicious mpMRI and entered biochemical follow-up. After a median (interquartile range) follow-up of 41 (23-57) months, 38 patients were diagnosed with PCa, of whom 13 (3.0%) had csPCa. The SIR for csPCa was 4.3 (95% confidence interval 2.3-7.4; total excess of eight cases). A higher risk of a positive biopsy for (cs)PCa based on the European Randomized Study of Screening for Prostate Cancer risk calculator and a suspicious repeat MRI (PI-RADS ≥3) were significant predictive factors for csPCa. CONCLUSION: After negative prior biopsy and non-suspicious mpMRI the risk of csPCa is low. However, compared to the general population, the risk of csPCa is increased despite the high negative predictive value of mpMRI. More research focusing on biochemical and image-guided risk-adapted diagnostic surveillance strategies is warranted.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Exterkate L, Wegelin O, Barentsz JO, et al. Incidence of significant prostate cancer after negative MRI and systematic biopsy in the FUTURE trial. BJU Int. 2022. PMID: 35993590. doi:10.1111/bju.15876

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。